recommendations on active ingredient, dose units, or formulations for a specific age group-for example, quinolones in children and xylometazoline 1% formulations for babies.
Comment
We found that 13.2% of prescriptions for a representative group of children in primary care in Germany were off label. Although we could not detect off label use due to dosage or indication with this database, the proportion of prescriptions that were off label was similar to that in much smaller studies that analysed dosage and diagnoses.
4 5 Our data show that efforts to improve the quality of pharmacotherapy in children should not exclude widely marketed and firmly established drugs. Studies in various hospital settings showed that many drugs taken by children either are not licensed or are used outside the terms of the product licence. 1-3 Information on the extent of paediatric labelling of drugs taken by children in the community is, however, limited and based on small study populations.
4 5 We studied drugs taken by children in the community, based on the pharmacy records of prescriptions from both general practitioners and outpatient departments. We aimed to determine the number of prescriptions for unlicensed drugs for children in the community and to investigate paediatric labelling of all drugs with a product licence to determine the extent of off label use.
Participants, methods, and results
In the Netherlands people commonly register with one pharmacy, from which they obtain their drugs, including those prescribed as outpatients. Excluded are drugs used during hospital stays and those bought over the counter. We obtained our data on dispensing from the InterAction database, which covers part of the northern Netherlands.
We selected all prescriptions for children aged 0-16 years in 2000. Dutch pharmacies are allowed to prepare their own formulations and to modify commercial preparations. These pharmacy based preparations are exempt from licensing, and we classified them as unlicensed. For each prescription of a licensed drug (all remaining prescriptions) we examined the official licence information-the summary of product characteristics-in detail. We determined whether the summary mentioned use in children and, if so, the minimum age. When age was unspecified we set it at a minimum of 0 years. If use in children was not mentioned or was advised against without an indication of age, we set the minimum age at 18 years. We considered that a drug with a product licence was used according to the label if the summary of product characteristics stated that it could be used in children, and if the child was of the minimum age for use or older; otherwise we considered the drug was used off label. As information about indications was not available, we were not able to distinguish between different indications in the summary.
We scriptions and were mainly dermatological and liquid preparations.
The table shows the official labelling of drugs prescribed for children. In 21.3% of the prescriptions for licensed drugs, use in children was not mentioned in the summary, and 19.7% mentioned use in children but without any indication of age. Although the summaries of remaining drugs indicated age, children were often divided into just two age groups.
Overall, 22.7% (15 453) of the prescriptions for children were used off label. Drug groups with the highest percentages of off label use were urologicals or sex hormones (mainly oral contraceptives; 85.9%), ophthalmological and otological drugs (79.4%), dermatological drugs (55.9%), and cardiovascular drugs (48.3%). In the group with the highest number of prescriptions-respiratory drugs-16.1% of all prescriptions were used off label.
Comment
Many licensed drugs used by children in the community are poorly labelled for use in children, resulting in high percentages of off label use. Therefore labelling for children needs to be improved, with the support of everyone working in pharmacotherapy.
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Methods and results
We retrieved data from the integrated primary care information project, a longitudinal observational database containing information from computer based patient records of 150 general practitioners in the Netherlands. The system complies with European Union guidelines on the use of medical data for medical research and has been proved valid for pharmacoepidemiological research.
2
Within the dynamic population of children (0-16 years) registered in 1998, we conducted a one year population based cohort study. From a source population of 53 702 eligible children, we randomly sampled 25% (n=13 426; 6941 (51.7%) boys), which formed our final study population. During the year 8271 (61.6%) children consulted their general practitioner at least once; the median was one consultation a year. We classified all 17 453 drug prescriptions issued to 6141 (45.7%) children according to the licensing status of the drug, 1 by reference to the official product licence, as provided by the Dutch Medicines Evaluation Board.
Seventy one per cent (12 405) of prescriptions were for drugs licensed for use in children and prescribed in agreement with the product licence. Of the remaining 5048 (28.9%) prescriptions, 2667 (15.3%, 95% confiInformation given in summary of product characteristics of drugs prescribed to children in the community in the Netherlands 
